WallStSmart

Caris Life Sciences, Inc. Common Stock (CAI)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Caris Life Sciences, Inc. Common Stock generates 122177% more annual revenue ($907.29M vs $742,000). CAI leads profitability with a 3.8% profit margin vs 0.0%. CAI earns a higher WallStSmart Score of 44/100 (D).

CAI

Hold

44

out of 100

Grade: D

Growth: 8.0Profit: 5.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -0.92

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CAI2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
78.8%10/10

Revenue surging 78.8% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

CAI4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
5.7%3/10

ROE of 5.7% — below average capital efficiency

Profit MarginProfitability
3.8%3/10

3.8% margin — thin

Operating MarginProfitability
2.4%3/10

Operating margin of 2.4%

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CAI

The strongest argument for CAI centers on Revenue Growth, Debt/Equity. Revenue growth of 78.8% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : CAI

The primary concerns for CAI are EPS Growth, Return on Equity, Profit Margin. Thin 3.8% margins leave little buffer for downturns.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

CAI profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

CAI is growing revenue faster at 78.8% — sustainability is the question.

CAI generates stronger free cash flow (23M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CAI scores higher overall (44/100 vs 24/100) and 78.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Caris Life Sciences, Inc. Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

CAI International, Inc. is a transportation finance company in the United States, Switzerland, France, Korea, Singapore, Rest of Asia, Rest of Europe, and internationally. The company is headquartered in San Francisco, California.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?